This is the guide we would want to read ourselves. No filler. No padding the list with compounds that have no evidence. Every peptide ranked here has a specific, evidence-rated reason for being on this list for women specifically.
The ranking is by goal because that is how women search. You do not wake up thinking “I need a GLP-1 receptor agonist.” You wake up thinking “I need to fix this weight plateau” or “my skin is aging faster than it should” or “why can I not sleep anymore.”
How We Ranked These
Three criteria: strength of evidence (human data beats preclinical), relevance to women specifically (female-predominant conditions, sex-specific mechanisms, or hormonal interactions), and practical accessibility (available through legal channels or reputable research vendors with COAs). Compounds that fail on any of these three are excluded regardless of hype.
Weight and Metabolism
1. Semaglutide — The Gold Standard
FDA-approved. 15% average weight loss. Superior to metformin for PMOS insulin resistance. Restores ovulatory cycles in 63% of PMOS patients. Cardiovascular benefit (20% MACE reduction in SELECT). Available by prescription.
2. Tirzepatide — Maximum Potency (Approved)
FDA-approved dual GLP-1/GIP agonist. 22.5% weight loss at highest dose. Particularly effective for visceral fat and hepatic steatosis. Contraceptive interaction warning for oral pills.
3. Retatrutide — The New Ceiling (Investigational)
Triple agonist (GLP-1/GIP/glucagon). 30.3% weight loss with no plateau. Not yet FDA-approved (NDA expected Q4 2026). Research-grade only. Muscle preservation is critical at this magnitude of loss.
4. MOTS-C — The Metabolic Peptide
Mitochondrial-derived, activates AMPK. Under PCAC review July 23 for obesity and osteoporosis. Dual metabolic-bone benefit makes it uniquely relevant for postmenopausal women.
Skin and Anti-Aging
1. GHK-Cu — The Collagen Rebuilder
Stimulates collagen I and III synthesis, increases elastin and SOD activity. Addresses the 30% collagen loss in the first 5 years post-menopause. Available topically and injectable. Comparable to retinol in studies with fewer side effects.
2. Epitalon — The Telomere Peptide
Synthetic tetrapeptide associated with telomerase activation. Under PCAC review July 24. Evidence is less robust than GHK-Cu but the mechanism (telomere maintenance) addresses a fundamental aging process. Highest evidence hurdle at PCAC.
3. NAD+ — The Cellular Energy Peptide
Supports mitochondrial function and cellular repair. NAD+ levels decline with age and metabolic stress. Relevant for energy, skin health, and neuroprotection. Multiple administration routes available.
Gut and Immune
1. BPC-157 — The Gut Protector
Mucosal protection, angiogenesis, anti-inflammatory. Under PCAC review July 23 for ulcerative colitis. IBS is 2x more common in women. Oral route preferred for gut applications. Pilot data in interstitial cystitis (10/12 women, 80-100% symptom resolution).
2. KPV — The Anti-Inflammatory
Tripeptide from alpha-MSH with potent anti-inflammatory activity. Strongest PCAC candidate (July 23). Autoimmune conditions affect women 4:1. Relevant for IBD, skin inflammation, and systemic autoimmune management.
3. Thymosin Alpha-1 — The Immune Modulator
Approved in 35+ countries for immune modulation. Relevant for Hashimoto's (5-8x female predominance) and other autoimmune conditions. Promotes T-cell balance and regulatory T-cell function.
Mood and Sleep
1. Selank — The Anxiolytic Peptide
GABA-enhancing, serotonin-modulating, BDNF-increasing. Approved in Russia for anxiety. Rapid onset (days vs weeks for SSRIs). No reported dependence or sexual side effects. Particularly relevant during perimenopause when anxiety prevalence spikes.
2. DSIP — The Sleep Peptide
Delta sleep-inducing peptide. Under PCAC review July 24. Promotes slow-wave sleep architecture. Relevant for perimenopausal insomnia. Evidence base is thin but the mechanism addresses a genuine unmet need.
Fertility and Hormonal
1. Kisspeptin-10 — The Ovulation Switch
Master regulator of the reproductive axis. Clinical trial data showing ovulation induction in PMOS with near-zero OHSS risk. Also emerging evidence for improving ovarian insulin resistance and sexual desire. The most versatile women's health peptide in the research pipeline.
2. PT-141 — The Desire Peptide
FDA-approved (Vyleesi) for HSDD in premenopausal women. MC4R agonist acting on central desire pathways. The only approved pharmacological treatment for female desire that works on the brain, not blood flow.
Recovery and Healing
1. BPC-157 + TB-500 — The Recovery Stack
BPC-157 for localized tissue repair. TB-500 for systemic healing support. Complementary mechanisms. Relevant for postpartum, post-surgical, and sports recovery. Both under PCAC review July 23.
2. CJC-1295/Ipamorelin — GH Optimization
Stimulates pulsatile growth hormone release. Supports lean mass, recovery, sleep quality, and skin thickness. Relevant for women in perimenopause when GH production is declining.
Bone Health
1. MOTS-C — The Bone Builder
Dual bone-building and anti-resorptive mechanism through AMPK activation. Under PCAC review. 80% of osteoporosis patients are women. Could become the first peptide-based anabolic bone therapy alongside existing options.
Where to Buy
FDA-approved peptides (semaglutide, tirzepatide, PT-141, orforglipron) require a prescription and are available through physicians and telehealth providers.
Research peptides are available from vendors for laboratory research purposes. We recommend vendors who provide third-party COAs, have established reputations in the research community, and maintain consistent product quality.
Not sure where to start? Take our quiz to match your goals to specific peptides.
Take the Peptide Quiz →